+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis

Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis

Journal of Cystic Fibrosis 5(2): 77-84

The objective of this study was to investigate the effect of docosahexaenoic acid (DHA) supplementation on blood and intestinal DHA levels and lung function in mild/moderately affected adult CF patients with the DeltaF508 genotype. Cystic Fibrosis (CF) patients often present with plasma fatty acid levels indicating low levels of linoleic (18:2n-6) and docosahexaenoic (22:6n-3) acids and an increased level of arachidonic acid (20:4n-6). Improved dietary fat intake or reducing fat malabsorption with pancreatic enzymes has failed to normalize this biochemical deficiency of DHA. Five CF patients, aged 18-43, received 70 mg of DHA/kg body weight/d for six weeks. At baseline and at six weeks a physical exam, lung function, 3-day dietary intake, duodenal mucosal biopsy and blood sample were assessed. The blood was analyzed for plasma vitamin A, D and E levels, liver function tests, clinical chemistry (CBC, differential and electrolytes). Plasma and red blood cell fatty acid levels were also analyzed. At three weeks, assessment included a physical exam, lung function test and fasting blood sample (vitamin levels, liver function and clinical chemistry only). Pre- and post-measurements were compared for the four subjects who completed the study. An increase in DHA content (% w/w) was observed in all phospholipid fractions of plasma, red blood cell and mucosal samples. No significant differences in vitamin levels, liver function or lung function were observed. The study proves the concept that an increase in tissue DHA levels in CF patients can be achieved by supplementing for six weeks with 70 mg/kg/d DHA.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 049071136

Download citation: RISBibTeXText

PMID: 16507353

DOI: 10.1016/j.jcf.2006.01.004

Related references

Changing eicosanoid precursor fatty acids and arachidonic/docosahexaenoic acid ratio by dietary intervention in patients with cystic fibrosis. gamma Linolenic acid: recent advances in biotechnology and clinical applications Second International Symposium on gamma Linolenic Acid, 91st AOCS Annual Meeting and Expo, San Diego, California, USA, April 2000: 207-216, 2001

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine 275(4): 428-436, 2014

Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Progress in Lipid Research 63: 132-152, 2016

Polyunsaturated fatty acid supplementation reverses cystic fibrosis-related fatty acid abnormalities in CFTR-/- mice by suppressing fatty acid desaturases. Journal of Nutritional Biochemistry 26(1): 36-43, 2015

Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels. Journal of Neurochemistry 146(2): 186-197, 2018

Effect of an 8-month treatment with omega -3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. Journal of Parenteral and Enteral Nutrition 27(1): 52-57, 2003

A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins Leukotrienes and Essential Fatty Acids 88(2): 163-169, 2013

Essential fatty acid-deprived tube-fed adults synthesize arachidonic and docosahexaenoic acids: a pilot analysis of the fatty acid status of people with profound developmental disabilities. Clinical Biochemistry 41(12): 1019-1021, 2008

An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clinical Biochemistry 40(8): 511-520, 2007

Two weeks of docosahexaenoic acid (DHA) supplementation increases synthesis-secretion kinetics of n-3 polyunsaturated fatty acids compared to 8 weeks of DHA supplementation. Journal of Nutritional Biochemistry 60: 24-34, 2018

The antibacterial properties of docosahexaenoic omega-3 fatty acid against the cystic fibrosis multiresistant pathogen Burkholderia cenocepacia. Fems Microbiology Letters 328(1): 61-69, 2012

Fatty acid supplementation in cystic fibrosis. Monographs in Paediatrics 10: 1-4, 1979

Docosahexaenoic acid supplementation in lactating women increases breast milk and plasma docosahexaenoic acid concentrations and alters infant omega 6:3 fatty acid ratio. Prostaglandins Leukotrienes and Essential Fatty Acids 95: 63-69, 2015

Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Current Opinion in Clinical Nutrition and Metabolic Care 8(2): 153-159, 2005

Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukotrienes and Essential Fatty Acids 77(5-6): 309-318, 2007